Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for United Therapeutics Corporation (UTHR : NSDQ)

• Company Description    United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Number of Employees: 1,400

• Price / Volume Information    Yesterday's Closing Price: $568.43 Daily Weekly Monthly 20 Day Moving Average: 415,129 shares Shares Outstanding: 42.45 (millions) Market Capitalization: $24,128.15 (millions) Beta: 0.60 52 Week High: $609.35 52 Week Low: $272.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.77% -5.62% 12 Week 12.87% 4.35% Year To Date 16.66% 6.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SPRING ST - SILVER SPRING,MD 20910 USA ph: 301-608-9292 fax: 301-608-9291 ir@unither.com http://www.unither.com

• General Corporate Information    Officers Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James C. Edgemond - Chief Financial Officer and Treasurer Paul A. Mahon - Executive Vice President; General Counsel; and Cor Christopher Causey - Director Peer Information United Therapeutics Corporation (GSAC) United Therapeutics Corporation (CASIF) United Therapeutics Corporation (ALCD.) United Therapeutics Corporation (OMNN) United Therapeutics Corporation (CGPI.) United Therapeutics Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 91307C102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/29/26 Share - Related Items Shares Outstanding: 42.45 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.60 Market Capitalization: $24,128.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $6.90 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $27.07 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 11.44% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/29/26

• Fundamental Ratios P/E Current FY Estimate: 21.00 Trailing 12 Months: 20.98 PEG Ratio: 1.84 Price Ratios Price/Book: 4.09 Price/Cash Flow: 17.23 Price / Sales: 7.61 EPS Growth vs. Year Ago Period: -12.22% vs. Previous Quarter: -24.42% Sales Growth vs. Year Ago Period: -1.62% vs. Previous Quarter: -1.10% ROE 03/31/26 - 19.24 12/31/25 - 19.30 09/30/25 - 18.83 ROA 03/31/26 - 17.25 12/31/25 - 17.29 09/30/25 - 16.75 Current Ratio 03/31/26 - 4.79 12/31/25 - 6.60 09/30/25 - 6.40 Quick Ratio 03/31/26 - 4.50 12/31/25 - 6.28 09/30/25 - 6.07 Operating Margin 03/31/26 - 40.62 12/31/25 - 41.94 09/30/25 - 40.65 Net Margin 03/31/26 - 40.62 12/31/25 - 41.94 09/30/25 - 40.65 Pre-Tax Margin 03/31/26 - 50.75 12/31/25 - 53.85 09/30/25 - 53.27 Book Value 03/31/26 - 139.02 12/31/25 - 164.81 09/30/25 - 153.06 Inventory Turnover 03/31/26 - 2.41 12/31/25 - 2.21 09/30/25 - 2.13 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©